Table 5.
Patient-Related Factors and HRQOL Outcomes 12 Months Post-TORS
| HNCI HRQOL Domain | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Variable | n | Speech function |
Speech attitude |
Eating function |
Eating attitude |
Aesthetic attitude |
Social function |
Social attitude |
Overall function |
Overall attitude |
Overall QOL |
| Sex | 0.30 | 0.60 | 0.06 | 0.13 | 0.61 | 0.14 | 0.64 | 0.07 | 0.27 | 0.21 | |
| Male | 35 | 78 (21) | 81 (23) | 55 (27) | 55 (30) | 84 (25) | 76 (29) | 83 (23) | 68 (22) | 77 (20) | 75 (20) |
| Female | 7 | 88 (13) | 86 (17) | 77 (26) | 74 (24) | 88 (24) | 93 (12) | 90 (12) | 84 (17) | 85 (15) | 86 (20) |
|
| |||||||||||
| Age | 0.25 | 0.03a | 0.43 | 0.30 | 0.04a | 0.23 | 0.44 | 0.38 | 0.17 | 0.11 | |
| ≥ 55 y | 26 | 84 (15) | 88 (14) | 61 (26) | 62 (28) | 91 (15) | 83 (24) | 86 (21) | 74 (17) | 82 (14) | 81 (19) |
| < 55 y | 16 | 72 (27) | 71 (27) | 54 (30) | 51 (33) | 73 (21) | 71 (32) | 81 (23) | 65 (27) | 70 (25) | 70 (21) |
|
| |||||||||||
| Smoking | 0.95 | 0.89 | 0.71 | 0.58 | 0.98 | 0.88 | 0.17 | 0.99 | 0.34 | 0.98 | |
| Smoker | 28 | 78 (21) | 80 (24) | 54 (28) | 55 (29) | 79 (27) | 76 (31) | 81 (24) | 67 (22) | 75 (21) | 78 (20) |
| Non-Smoker | 14 | 84 (19) | 85 (17) | 68 (25) | 63 (33) | 94 (15) | 84 (19) | 91 (12) | 77 (20) | 83 (14) | 75 (22) |
|
| |||||||||||
| HPV | 0.43 | 0.47 | 0.70 | 0.96 | 0.97 | 0.81 | 0.57 | 0.99 | 0.56 | 0.72 | |
| HPV + | 31 | 79 (19) | 80 (19) | 60 (26) | 58 (29) | 84 (21) | 78 (27) | 83 (21) | 71 (21) | 77 (17) | 75 (22) |
| HPV − | 8 | 81 (28) | 81 (33) | 54 (37) | 56 (36) | 78 (36) | 75 (32) | 83 (27) | 67 (29) | 76 (30) | 78 (16) |
|
| |||||||||||
| Site | 0.86 | 0.56 | 0.80 | 0.83 | 0.91 | 0.72 | 0.99 | 0.88 | 0.73 | 0.46 | |
| Tonsil | 35 | 80 (20) | 81 (22) | 58 (27) | 58 (29) | 83 (25) | 79 (29) | 84 (23) | 70 (21) | 78 (20) | 78 (20) |
| BOT | 7 | 78 (23) | 84 (22) | 62 (32) | 60 (36) | 88 (19) | 77 (24) | 87 (14) | 71 (26) | 80 (18) | 71 (22) |
|
| |||||||||||
| pT | 0.75 | 0.86 | 0.35 | 0.70 | 0.95 | 0.50 | 0.53 | 0.45 | 0.73 | 0.86 | |
| T1/T2 | 38 | 81 (21) | 82 (22) | 59 (29) | 58 (31) | 84 (24) | 77 (28) | 84 (22) | 71 (23) | 78 (20) | 77 (22) |
| T3/T4 | 4 | 70 (16) | 75 (21) | 53 (5) | 53 (5) | 88 (25) | 90 (21) | 88 (15) | 65 (9) | 77 (17) | 75 (1) |
|
| |||||||||||
| pN | 0.88 | 0.87 | 0.77 | 0.93 | 0.40 | 0.48 | 0.25 | 0.80 | 0.60 | 0.48 | |
| N0 | 7 | 76 (29) | 79 (35) | 66 (37) | 68 (40) | 79 (39) | 75 (35) | 79 (27) | 71 (33) | 77 (33) | 79 (22) |
| N+ | 34 | 80 (19) | 82 (19) | 57 (26) | 55 (28) | 85 (21) | 79 (27) | 85 (20) | 70 (19) | 78 (16) | 76 (20) |
|
| |||||||||||
| Overall Stage | 0.66 | 0.70 | 0.90 | 0.77 | 0.88 | 0.25 | 0.12 | 0.95 | 0.62 | 0.41 | |
| I/II | 5 | 73 (33) | 76 (42) | 61 (41) | 61 (46) | 70 (45) | 67 (39) | 70 (28) | 66 (37) | 70 (38) | 75 (25) |
| III/IV | 36 | 81 (19) | 82 (18) | 58 (26) | 57 (28) | 86 (21) | 80 (26) | 86 (20) | 71 (20) | 79 (16) | 76 (20) |
|
| |||||||||||
| Extent of TORS | 0.43 | 0.13 | 0.80 | 0.80 | 0.70 | 0.40 | 0.86 | 0.49 | 0.93 | 0.33 | |
| 1 Site | 22 | 78 (22) | 77 (25) | 57 (26) | 56 (31) | 80 (29) | 77 (31) | 82 (25) | 69 (23) | 75 (22) | 80 (21) |
| > 1 Site | 19 | 83 (18) | 86 (17) | 61 (30) | 60 (30) | 89 (17) | 80 (24) | 87 (17) | 72 (21) | 82 (15) | 74 (19) |
|
| |||||||||||
| XRT | 0.007a | 0.01a | 0.003a | 0.005a | 0.06 | 0.09 | 0.10 | 0.002a | 0.003a | 0.13 | |
| No XRT | 5 | 98 (3) | 98 (4) | 91 (14) | 90 (11) | 100 (1) | 97 (7) | 96 (8) | 94 (7) | 96 (2) | 90 (14) |
| XRT | 37 | 78 (21) | 79 (22) | 54 (26) | 53 (29) | 82 (25) | 76 (29) | 82 (22) | 67 (21) | 75 (19) | 75 (20) |
|
| |||||||||||
| CRT | 0.10 | 0.05 | 0.04a | 0.04a | 0.20 | 0.27 | 0.26 | 0.006a | 0.04a | 0.31 | |
| No CRT | 5 | 87 (24) | 91 (20) | 79 (24) | 78 (22) | 95 (11) | 88 (18) | 93 (10) | 84 (22) | 89 (15) | 85 (22) |
| CRT | 25 | 78 (19) | 80 (24) | 53 (23) | 53 (29) | 80 (27) | 75 (26) | 82 (21) | 66 (19) | 75 (20) | 75 (20) |
|
| |||||||||||
| Adjuvant Treatment | 0.76 | 0.72 | 0.74 | 0.95 | 0.41 | 0.37 | 0.55 | 0.42 | 0.91 | 0.99 | |
| XRT | 12 | 76 (25) | 78 (20) | 56 (32) | 53 (31) | 86 (22) | 78 (35) | 84 (27) | 70 (26) | 76 (19) | 75 (22) |
| CRT | 25 | 78 (19) | 80 (24) | 53 (23) | 80 (27) | 75 (26) | 82 (20) | 82 (20) | 66 (19) | 75 (20) | 75 (20) |
|
| |||||||||||
| G-Tube | 0.99 | 0.42 | <0.001a | <0.001a | 0.92 | 0.98 | 0.98 | 0.20 | 0.27 | 0.93 | |
| No G-Tube | 40 | 80 (20) | 82 (22) | 60 (27) | 60 (30) | 84 (25) | 79 (28) | 84 (21) | 71 (22) | 79 (20) | 77 (20) |
| G-Tube | 2 | 78 (32) | 73 (25) | 29 (15) | 25 (12) | 88 (18) | 79 (29) | 84 (22) | 54 (7) | 68 (15) | 75 (35) |
Abbreviations: HNCI, Head and Neck Cancer Inventory; HRQOL, Health Related Quality of Life; n, number; y, years; HPV, Human Papilloma Virus; BOT, Base of Tongue; pT, pathologic Tumor-classification; pN, pathologic Node-classification; N+, pathologically positive neck; TORS, transoral robotic surgery; XRT, post-operative external beam radiation therapy; CRT, post-operative chemo-radiation therapy; G-Tube, gastrostomy tube.
Data are given as: p-value; mean (standard deviation)
a
Denotes statistical significance